Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy

Abstract excerpt

The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour-associated antigen, fused to a component of the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Synthesis and Biological Evaluation